Jesús
San Miguel Izquierdo
Consultor Investigador
Icahn School of Medicine at Mount Sinai
Nueva York, Estados UnidosPublicacións en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (15)
2024
-
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Clinical Lymphoma, Myeloma and Leukemia
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
2022
-
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154
-
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Journal of Clinical Pharmacology, Vol. 61, Núm. 5, pp. 614-627
-
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716
-
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)
Haematologica, Vol. 106, Núm. 6, pp. 1725-1732
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
The Lancet, Vol. 398, Núm. 10301, pp. 665-674
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Blood Cancer Journal, Vol. 10, Núm. 11
2019
-
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 8, pp. 668-677
2018
-
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX
Haematologica, Vol. 103, Núm. 12, pp. 2088-2096
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051